Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2020 Aug 26;19(10):2057–2067. doi: 10.1158/1535-7163.MCT-20-0134

Figure 4: In vivo specificity of chimeric MV in an EGFR positive human ovarian tumor xenograft model.

Figure 4:

MVCDVenv-EGFR is specifically oncolytic in i.p. EGFR positive SKOV3i.p.1-Fluc tumors treated 10 days after tumor implantation with 6 doses of 2 X 106 TCID50 of indicated virus treatment or control (n=3 control and n=4 for treatment group). (A) Serial bioluminescent imaging on the indicated days. (B) Overall survival of treated animals. ns = not significant; * p<0.05